Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Esperavir (Molnupiravir) in Adult Outpatients with COVID-19
NCT05595824Phase 3Completed
- Sponsor
- Promomed
- Start
- Dec 2021
- Primary completion
- Mar 2022
- Modality
- RNA-Targeting Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Esperavir with Standard of Care (2 arms). Primary endpoint: Prevalence of patients with COVID-19 severity increase. Started Dec 2021; status: completed.
02
Drugs
molnupiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05595824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05595824.